Edmonston, D., Mulder, H., Lydon, E., Chiswell, K., Lampron, Z., Shay, C. M., … Pagidipati, N. (2023). Comparative Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. In JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (Vol. 34, pp. 856–857).

Edmonston, Daniel, Hillary Mulder, Elizabeth Lydon, Karen Chiswell, Zachary Lampron, Christina M. Shay, Keith A. Marsolo, Hayden Bosworth, and Neha Pagidipati. “Comparative Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.” In JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 34:856–57, 2023.

Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay CM, et al. Comparative Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. In: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2023. p. 856–7.

Edmonston, Daniel, et al. “Comparative Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.” JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 34, no. 11, 2023, pp. 856–57.

Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay CM, Marsolo KA, Bosworth H, Pagidipati N. Comparative Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2023. p. 856–857.